Trial Profile
Randomized Phase II, study to evaluate the efficacy of Paclitaxel in monotherapy vs Paclitaxel + Cetuximab (Erbitax) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma that has progressed to extreme-type first line chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2012
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Paclitaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms EXTAX
- 20 Oct 2012 According to European Clinical Trails Database this study has been ended prematurely
- 27 Jun 2011 New trial record